Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Core Innovation
The invention relates to physically stable oil-in-water intravenous pharmaceutical compositions comprising aprepitant formulated as a stable emulsion. The formulations are defined by specific weight-percent amounts of aprepitant, egg yolk lecithin, and soybean oil, and are characterized as physically stable with reduced creaming and cracking over shelf life. The compositions are additionally controlled by a pH modifier, where the pH modifier is sodium oleate.
The invention solves the problem of providing stable intravenous emulsion formulations of aprepitant by controlling both physical stability and chemical stability while maintaining a specified emulsion pH. The described formulations include a composition pH ranging from 7.5 to 9.0, and employ a ratio of egg yolk lecithin to aprepitant (wt %:wt %) ranging from about 18:1 to 22:1. Physical stability is supported by emulsion characterization results including droplet size and PFAT5 values.
In particular embodiments, the invention provides physically stable intravenous pharmaceutical compositions including fixed or narrowed ranges for aprepitant, egg yolk lecithin, and soybean oil, together with sodium oleate as the pH modifier. Optional excipients discussed in the document include ethanol and sucrose, and the formulations are evaluated for stability behavior including freeze-thaw performance and measured particle size and zeta potential. The disclosed compositions further demonstrate co-release with dexamethasone sodium phosphate while maintaining aprepitant pharmacokinetics in the documented animal study.
Claims Coverage
Two independent claims are directed to physically stable pharmaceutical compositions for intravenous administration. Each independent claim specifies compositional constraints that define the stable emulsion, including aprepitant, egg yolk lecithin, soybean oil, sodium oleate pH control, and a defined pH range; the first independent claim additionally specifies an egg yolk lecithin-to-aprepitant ratio constraint.
Physically stable composition of aprepitant with egg yolk lecithin, soybean oil, and sodium oleate pH modifier
A physically stable pharmaceutical composition comprising 0.4 wt/wt % to 1.0 wt/wt % aprepitant, 13 wt/wt % to 15 wt/wt % egg yolk lecithin, 9 wt/wt % to 10 wt/wt % soybean oil, and a pH modifier wherein the pH modifier is sodium oleate.
Defined emulsion pH and egg yolk lecithin-to-aprepitant ratio
Wherein the pH of the composition ranges from 7.5 to 9.0 and wherein the ratio of egg yolk lecithin to aprepitant (wt %:wt %) ranges from about 18:1 to 22:1.
Physically stable intravenous pharmaceutical composition with defined aprepitant, egg yolk lecithin, soybean oil, and sodium oleate
A physically stable pharmaceutical composition suitable for intravenous administration comprising 0.7 wt/wt % aprepitant, 14 wt/wt % egg yolk lecithin, 9 wt/wt % to 10 wt/wt % soybean oil, and a pH modifier wherein the pH modifier is sodium oleate.
Defined emulsion pH for intravenous formulation
Wherein the pH of the composition ranges from 7.5 to 9.0.
The claim coverage centers on physically stable intravenous emulsion compositions of aprepitant that require sodium oleate as the pH modifier, a defined pH range of 7.5–9.0, and tightly specified egg yolk lecithin and soybean oil content. One independent claim further imposes a specific wt % ratio constraint between egg yolk lecithin and aprepitant.
Stated Advantages
Physical stability of the oil-in-water intravenous emulsion formulation (reduced creaming and cracking over shelf life).
Emulsion physical stability characterized by droplet size and PFAT5 over shelf life.
Controlled pH (pH ranges from 7.5 to 9.0) using sodium oleate.
Chemical stability in the disclosed formulations.
Freeze-thaw performance, including performance of sucrose-rich formulation.
In documented animal pharmacokinetics, emulsion bioavailability and co-release with dexamethasone sodium phosphate without affecting aprepitant pharmacokinetics.
Documented Applications
Treating nausea and vomiting by administering a pharmaceutical composition defined by the claims to a subject in need.
Chemotherapy-induced nausea and vomiting treatment.
Chemotherapy-induced nausea and vomiting treatment for highly emetic chemotherapy.
Use of the composition as a physically stable pharmaceutical composition suitable for intravenous administration.
Interested in licensing this patent?